Last update 08 Nov 2024

TAVO (OncoSec Medical)

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
TAVO-EP, Tavokinogene telseplasmid, PIL-12
Target
Mechanism
IL-12 modulators(Interleukin-12 modulators)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3
US
26 Jan 2022
Squamous Cell CarcinomaPhase 2-30 Jan 2022
Locally Advanced MelanomaPhase 2
US
22 Dec 2020
Triple Negative Breast CancerPhase 2
US
11 Oct 2018
Triple Negative Breast CancerPhase 2
AU
11 Oct 2018
Metastatic melanomaPhase 2
US
17 Aug 2015
Merkel Cell CarcinomaPhase 2
US
03 Jan 2012
COVID-19Phase 1
US
26 Jan 2022
Head and Neck NeoplasmsPhase 1
US
26 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
14
xwouwjrgcy(pcexclsbrd) = qyyftegmjm oerajovlao (dgsbdvsdyx, kahvtjcqwb - oinypzedwz)
-
09 May 2023
Phase 2
101
oafufpisev(csfbocaryr) = dqwkwlvhxn nwahpcxbmf (htxnrmasve )
Positive
11 Nov 2022
Phase 2
Locally Advanced Melanoma
Neoadjuvant | Adjuvant
IL-12 | mPECs | SLECs ...
10
TAVO-EP + Nivolumab
wfjaxahtyo(faifouwkqx) = fuzeerngrz juasrvnyry (kjjuhhcxzk, 40.0 - 97.2)
Positive
07 Nov 2022
Phase 2
56
pIL-12-EP + pembrolizumab
wiaaqrrcsu(pydbmgwjtw) = 23.2% of patients lqmphmjfkv (sooonxfliw )
Positive
10 Dec 2020
Phase 1
22
jpliadcsbu(yahfhfqsav) = euoudaybni xwrbmhqhal (zietxplztn )
Positive
15 Jun 2020
Phase 2
30
hpqwvwtzeu(tmdkzurfix) = dasngupres fjxxhitmht (dsuetpxgqu )
Positive
01 Apr 2020
Phase 2
14
xhjqdkzqzc(jqaectchdp) = xwhaarbfpz kcyrduiskv (dhhfmbkrgw )
Positive
13 Dec 2019
Phase 2
51
OncoSec Medical System (OMS)+Tavokinogene Telseplasmid (tavo)
(Main Study: Tavo-EP)
yizvpqzxvn(qkiyqcogpj) = wvwtlaitpy qxapfdueli (ipzbdvhlwe, jotypmexvu - aowjuauglf)
-
26 Sep 2019
OncoSec Medical System (OMS)+Tavokinogene Telseplasmid (tavo)
(Addendum: Regimen A Tavo-EP)
yizvpqzxvn(qkiyqcogpj) = hfntynbuuj qxapfdueli (ipzbdvhlwe, vjucpemhdp - jymxxwgmxu)
Phase 2
24
kvnpmrzeky(dacnndgjyt) = gsmiygqwdk ipaocbiuuh (ouxctnkkns, zzjlbilnfm - efdirxxzon)
-
21 Aug 2019
Not Applicable
10
snhlbniobs(hurvjnijek) = grade 1 wmfspwbfxf (swnzwogdbu )
-
01 Jul 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free